Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 4,918 recruiting studies in this area right now.
By phase
- Not applicable2,022
- Phase 21,072
- Phase 1792
- Phase 1/Phase 2478
- Phase 3345
- Phase 4126
- Phase 2/Phase 383
Top conditions
- Multiple Myeloma327
- Acute Myeloid Leukemia281
- Lymphoma178
- Sickle Cell Disease134
- Myelodysplastic Syndromes128
- Acute Lymphoblastic Leukemia118
- Leukemia100
- Chronic Lymphocytic Leukemia95
- Follicular Lymphoma70
- Hematologic Malignancy67
- Myelodysplastic Syndrome64
- Hodgkin Lymphoma63
- Mantle Cell Lymphoma62
- Anemia56
- Diffuse Large B Cell Lymphoma54
- Malignant Solid Neoplasm53
- Acute Myeloid Leukemia (AML)48
- Lymphedema48
Leading sponsors
- M.D. Anderson Cancer Center145
- Institute of Hematology & Blood Diseases Hospital, China138
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University67
- Memorial Sloan Kettering Cancer Center63
- City of Hope Medical Center58
- Mayo Clinic55
- Assistance Publique - Hôpitaux de Paris45
- St. Jude Children's Research Hospital44
- Peking University People's Hospital43
Where studies are running
- California396
- Texas185
- Alabama156
- Maryland152
- Arizona125
- Florida105
- Massachusetts103
- New York98
- Ohio70
- Minnesota69
Recruiting studies4,918 total
- NCT06581640RecruitingPhase 2
BCMA-targeting CAR-T cells for relapsed/refractory myeloma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
Xiamen, FujianAges 18–80 - NCT06238648RecruitingPhase 2
Epcoritamab for B-cell lymphoma after CAR-T therapy
This trial tests if the drug epcoritamab can help people with B-cell lymphoma whose cancer showed only a partial response 30 days after CAR-T cell therapy. It compares epcoritamab to simply monitoring the condition.
Rochester, MinnesotaAges 18 years+ - NCT06615193RecruitingPhase 1
Testing a new drug for certain blood and solid tumors
This study tests a new drug, HDM2005, for people with relapsed or hard-to-treat B-cell lymphoma or advanced solid tumors. The goal is to see if it is safe and effective.
Zhengzhou, HenanAges 18 years+ - NCT06130787Recruiting
Using your body's age to personalize CML treatment
This study looks at how your 'biological age' (how old your body seems) affects how well you do on targeted therapy for chronic myeloid leukemia. It aims to personalize your care by combining age and frailty information.
AnnecyAges 18 years+ - NCT04638790RecruitingPhase 3
First treatment chemotherapy study for newly diagnosed Hodgkin lymphoma
This trial studies the best first chemotherapy approach for people newly diagnosed with classical Hodgkin lymphoma. It may help improve outcomes by comparing how treatment is given in routine care settings in Russia.
Mumbai, Opd-81 Main Building, Dr. E Borges Road, Parel 400012Ages 18–50 - NCT06471946RecruitingPhase 1/Phase 2
Stem cell transplant for older patients with high-risk MDS
This trial tests a special conditioning regimen (VA) before a stem cell transplant for older patients with higher-risk myelodysplastic syndrome (MDS). It aims to make the transplant safer and more effective for this group.
Beijing, Beijing MunicipalityAges 70 years+ - NCT06621199RecruitingPhase 2
Three-drug combination for newly diagnosed AML in older adults
This clinical trial tests a combination of three drugs: a liposomal form of mitoxantrone (a type of chemotherapy), cytarabine (another chemo drug), and venetoclax (a targeted therapy). The goal is to see if this combination is safe and works well for older adults (ages 60-70) who have just been diagnosed with AML and cannot have standard intensive chemotherapy.
Hangzhou, ZhejiangAges 60–70 - NCT07734038RecruitingPhase 2
Venetoclax and Zanubrutinib for CLL and SLL
This study tests a combination of two oral medications, venetoclax and zanubrutinib, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). It aims to see if this combination is safe and effective, either as a first treatment or after a previous treatment.
Columbus, OhioAges 18 years+ - NCT07739654RecruitingPhase 3
Modified chemotherapy combo for relapsed large b-cell lymphoma
This study compares two chemotherapy regimens for people with diffuse large B-cell lymphoma that has returned or not responded to earlier treatment. The goal is to see if a modified version is as effective with fewer side effects.
Lahore, Punjab ProvinceAges 18 years+ - NCT07735533RecruitingPhase 1/Phase 2
UB-VV400 with rapamycin for large B-cell lymphoma
This trial tests an experimental treatment called UB-VV400 given with another drug, rapamycin, for people with large B-cell lymphoma that has not responded to standard therapy. The treatment targets a protein called CD22 on lymphoma cells and may help your immune system fight the cancer.
Nashville, TennesseeAges 18 years+ - NCT05751447Recruiting
Studying immune cells in suspected sarcoidosis
This study looks at immune cells in the lungs, lymph nodes, and blood to learn more about suspected sarcoidosis. You may benefit by helping researchers better understand the condition and by getting close medical evaluation as part of the study.
StockholmAges 18–90 - NCT07727642Recruiting
Optimizing HIV Medicines for AIDS-Related Lymphoma
This trial helps doctors find the best way to combine HIV medicines (antiretroviral therapy) with lymphoma treatment for people who have both HIV and AIDS-related lymphoma. The goal is to improve your overall care and outcomes.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07724756RecruitingPhase 2
Testing QLC2519 with chemotherapy for pediatric sarcoma
This trial tests a new drug (QLC2519) given alongside a standard chemotherapy regimen called VDC/IE for children and teens with sarcoma. The goal is to see if it can help treat their cancer more effectively.
BeijingAges birth–18 years - NCT07730515RecruitingPhase 1/Phase 2
Study of XNW5004 plus chemo for untreated T-cell lymphoma
This trial tests a new drug called XNW5004 combined with standard chemotherapy for people who have just been diagnosed with peripheral T-cell lymphoma and haven't had treatment yet. The goal is to see if adding XNW5004 helps more than chemotherapy alone.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06626893Recruiting
Leukemia study using advanced tests to find targeted treatment
This study uses advanced tests (genetics and other 'omics' methods) to better understand your leukemia and find a treatment that targets its specific features. It may help if standard treatments haven't worked or stopped working.
Meldola, Forlì-CesenaAges 18 years+ - NCT07725263Recruiting
Low-dose antifungal for kids with low white blood cells
This trial tests a low dose of an antifungal medicine (liposomal amphotericin B) to prevent serious fungal infections in children whose immune system is weak after cancer treatment or a stem cell transplant. It's for kids aged 3 to 17 who are at high risk for these infections.
Haikou, HainanAges 3–17 - NCT07727083Recruiting
Study of EBV-positive T/NK-cell lymphoma and related diseases
This study collects medical information and blood samples from people with Epstein-Barr virus-positive T/NK-cell lymphoproliferative diseases to better understand how these conditions progress and respond to treatment. It includes a retrospective part (looking back at medical records) and a prospective part (following people forward in time).
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07724873RecruitingPhase 1/Phase 2
Withaferin A to prevent GVHD after stem cell transplant
This study tests a natural compound called Withaferin A (from ashwagandha) to see if it helps prevent graft-versus-host disease (GVHD) after a stem cell transplant. The goal is to reduce the risk of transplant complications.
Navi Mumbai, MaharashtraAges 18 years+ - NCT07725497RecruitingPhase 2
Luspatercept for anemia from chronic kidney disease
This trial tests a drug called luspatercept to see if it can raise hemoglobin levels in people with anemia caused by chronic kidney disease. It's for those whose current treatments aren't working well or who cannot use them.
Basking Ridge, New JerseyAges 18 years+ - NCT07730996Recruiting
Nutrition care for hospital patients
This trial tests a new way of providing nutrition care to patients while they are in the hospital. It aims to see if having a dietitian closely involved in patient care can improve their nutritional health. If you are admitted to a participating ward, you might be included.
HerningAges 18 years+ - NCT04598750Recruiting
Assessing bleeding risk in very premature babies with low platelets
This trial looks at how to estimate bleeding risk in newborns who are very premature and have a low platelet count. The goal is to guide safer care by better identifying which babies may be at higher risk of bleeding.
Boston, MassachusettsAges 1 day+ - NCT05790733Recruiting
Communication training versus usual care for feeding tube placement
This study compares a special communication approach to the usual method when placing a naso-gastric (feeding) tube in people receiving chemotherapy. It aims to see whether better communication can make tube placement easier and more tolerable.
Rennes, Brittany RegionAges 18 years+ - NCT06633354RecruitingEarly Phase 1
CD5-targeted CAR T-cells for relapsed/refractory T-ALL
This trial tests a new type of immune therapy—called CD5-targeting CAR T-cells—for people with a hard-to-treat form of T-cell acute lymphoblastic leukemia. It aims to see if these specially designed cells can find and destroy leukemia cells with the CD5 marker.
Hangzhou, ZhejiangAges Any age - NCT06633341RecruitingEarly Phase 1
CAR-T cell therapy for CD5+ T-cell lymphoma
This trial tests a new treatment using your own immune cells, engineered to find and attack cancer cells that have a protein called CD5. It is for people with a type of T-cell lymphoma that has come back or not responded to other treatments.
Hangzhou, ZhejiangAges Any age
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 4,918 recruiting hematology studies from the U.S. registry right now, out of 7,266 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.